http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2894324-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e15581e7a25ac454131cda209024272b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2016-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6e5c72406ded8bb70d245de568770cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_468235eaf8cffb147d5495d58965234d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de0dcfb2d815c021fb4934fbd751c723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b64520de2be1f06bdf103c626e983807 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64e3b57d4ef390d8609fdefc0fd1edf0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32ca78d10b49277ea44de58c2f0c4f67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c1ff43bbe34d0dad2ac07c5fcfbde36 |
| publicationDate | 2022-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2894324-T3 |
| titleOfInvention | Dextrorphan derivatives with suppressed central nervous activity |
| abstract | A dextrorphan derivative according to general formula (I) **(See formula)** in which R1 is selected from -OH, -CO2H, -R0, -OR0, -OC(=O)R0, -OC(= O)OR0 or -OC(=O)NHR0; R2 is selected from -H, -R0, -C(=O)R, -C(=O)OR0, -C(=O)NHR0, or -C(=NH)-NH-C(=NH)- NH2; X is selected from -F, -Cl, -Br, -I, or -NR3R4, where R3 and R4 are independently selected from -H or -R0; or wherein R3 and R4, together with the nitrogen atom to which they are attached, form a three-, four-, five-, six-, or seven-membered heterocycloalkyl or heteroaryl ring, each independently substituted or unsubstituted; wherein R0 is each independently selected from -C1-C6 alkyl, -aryl, -heteroaryl, -C1-C6 alkyl-aryl, or -C1-C6 alkyl-heteroaryl, each independently substituted or unsubstituted substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios; for use in the treatment and/or prophylaxis of diseases or conditions selected from insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, latent autoimmune diabetes in adults (LADA), obesity, nephropathy, retinopathy, stroke, cardiovascular disease, such as myocardial infarction , and endothelial dysfunction. |
| priorityDate | 2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 730.